Long-Term Follow Up After Third Party Viral-Specific Cytotoxic Lymphocytes For Immunosuppression- And Epstein-Barr Virus-Associated Lymphoproliferative Disease

Sajida Kazi, Abhinav Mathur, Gwen Wilkie, Kirsty Cheal, Richard Battle, Neil McGowan, Neil Fraser, Emily Hargreaves, David Turner, John D. M. Campbell, Marc Turner, Mark A. Vickers* (Corresponding Author)

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

25 Citations (Scopus)

Abstract

Epstein-Barr virus (EBV)-associated lymphoproliferative disease is a serious complication of immunosuppression, particularly after transplantation. Treatment by reduction of immunosuppression risks graft loss after solid organ transplantation (SOT) and only 25-50% of patients respond.
Original languageEnglish
Pages (from-to)e356-e359
Number of pages4
JournalHaematologica
Volume104
Issue number8
Early online date21 Feb 2019
DOIs
Publication statusPublished - Aug 2019

Bibliographical note

The authors would like to thank the Wellcome Trust for funding the initial set up of this bank, and the blood donors from New Zealand who provided cells.

Keywords

  • T-CELL THERAPY
  • DISORDER
  • RISK
  • MANAGEMENT
  • RECIPIENTS

Fingerprint

Dive into the research topics of 'Long-Term Follow Up After Third Party Viral-Specific Cytotoxic Lymphocytes For Immunosuppression- And Epstein-Barr Virus-Associated Lymphoproliferative Disease'. Together they form a unique fingerprint.

Cite this